Gossamer Bio and Chiesi Farmaceutici S.p.A, an international, research-focused biopharmaceutical group, entered into a global collaboration and license agreement to develop and commercialize seralutinib in May 2024.
This global collaboration combines the strengths of both Chiesi and Gossamer Bio to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate development in pulmonary hypertension associated with interstitial lung disease (PH-ILD), enabling the expansion of the seralutinib franchise to reach more patients with pulmonary hypertension world-wide. Patients will benefit from both Chiesi’s expertise in global respiratory, rare disease, and inhaled drug development and commercialization, and Gossamer Bio’s world-class PAH and PH-ILD development and commercialization teams.
Under the terms of the agreement, Gossamer Bio leads the global development of seralutinib in PAH and PH-ILD, and the companies will evenly split development costs, except with respect to the PROSERA Study, for which Gossamer Bio will remain financially responsible.
In the US, the companies will evenly share commercial profits and losses. Gossamer Bio will lead commercialization and book sales for PAH and PH-ILD in the US, with both companies contributing 50 percent of commercial efforts. Chiesi will lead US commercialization in additional indications.
Chiesi will have the exclusive right to commercialize seralutinib outside of the US and will pay Gossamer Bio an escalating mid-to-high teens royalty on net sales. Gossamer Bio will also be eligible to receive up to $146 million in regulatory milestones and $180 million in sales milestones.
